Rho, Jin Kyung

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,224

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors

Choi, Y. J., Rho, J. K., Jeon, B.-S., Choi, S. J., Park, S. C., Lee, S. S., Kim, H.-R., Kim, C. H., & Lee, J. C. (2010) · Cancer Chemotherapy and Pharmacology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 63

HIF-1α modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines

Choi, Y. J., Rho, J. K., Lee, S. J., Jang, W. S., Lee, S. S., Kim, C. H., & Lee, J. C. (2009) · Journal of Cancer Research and Clinical Oncology

Cancer, Hypoxia, and MetabolismCancer therapeutics and mechanisms

Cited by 25